Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
23 February 2017
E-007539/2016
Answer given by Ms Bieńkowska on behalf of the Commission

1. Biomedical research requires heavy investment and long-term research, coupled with expensive clinical trials and demanding regulatory approval and post-approval procedures. Intellectual Property Rights (IPRs) provide an important incentive for pharmaceutical and biomedical research. The Commission seeks to strike the right balance between the need to promote and finance the research and development of innovative medicines through IPR protection, and to ensure that medicines are accessible to those in need and health systems remain sustainable.

Any amendment of the pharmaceutical IPR framework would need to be justified by an evidence-based analysis. As requested by the Council(1), the Commission will carry out, as soon as possible, and with the close involvement of the Member States, an evidence-based analysis of the impact of pharmaceutical incentives and rewards (including IPRs) on innovation, availability and accessibility of medicinal products in the EU. The timetable and methodology that the Commission intends to apply was presented at the EPSCO Council on 8 December 2016(2).

2. Information on funding for projects supported through Horizon 2020 is fully transparent(3) Beyond the costs for the projects to be implemented under an EU research grant, Horizon 2020 does not provide for the obligation of beneficiaries to disclose costs not related to the implementation of such grants.

(1)Council Conclusions on ‘Strengthening the balance in the pharmaceutical systems in the European Union and its Member States’ of 17 June 2016, paragraph 47.
(2)http://data.consilium.europa.eu/doc/document/ST-14568-2016-INIT/en/pdf
(3)Community Research and Development Information Service — http://cordis.europa.eu

Last updated: 6 March 2017Legal notice